IL2 and graft versus host disease: A clinical trial of in vivo Treg expansion by injection of ultra-low dose IL-2 also reduced the incidence of GVHD (111); 16 patients were administered with ultra-low doses of IL-2 (100,000 units subcutaneously × 3 weekly for 6–12 weeks) after allo-HSCT.